secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066924
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q1 net loss $28.1M; cash $318.9M; BEACH301 achondroplasia study open
--------------------------------------------------------------------------------

- Net loss $28.1M vs $18.2M in Q1 2024; R&D expense $25.0M (up 45% YoY) driven by clinical start-up costs.
- Cash, equivalents, and marketable securities $318.9M as of March 31, 2025; runway through at least 2027.
- BEACH301 Phase 2 study of TYRA-300 for pediatric achondroplasia now enrolling safety sentinel cohort.
- SURF431 Phase 1 study of TYRA-430 (FGFR4/3 inhibitor) in HCC initiated; first patient dosed.
- SURF302 Phase 2 NMIBC study of TYRA-300 expected to dose first patient in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017025066924/0000950170-25-066924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017025066924/tyra-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer